FRAGMENT-BASED DRUG DESIGN OF INDAZOLE DERIVATIVES AS POTENTIAL ANTIPARASITIC AGENTS

- 341754
Abstract
Favorite this paper
How to cite this paper?
Abstract

Leishmaniasis and trypanosomiasis are parasitic diseases that affect tropical regions and are considered neglected tropical diseases (NTDs).1 These diseases still require the development of more effective and safer therapies.2 Fragment-based drug design (FBDD) emerged as an excellent means to discover promising treatment options. Indazole, the fragment of choice, was subjected to various synthetic transformations and molecular characterization by Nuclear Magnetic Resonance (NMR), Liquid Chromatography-Mass Spectrometry (LC-MS) and High-Resolution Mass Spectrometry (HRMS). Phenotypic biological screening against a panel of parasites (IC₅₀) and test for cytotoxicity (TC50) showed compounds with promising antiparasitic activities. Two libraries of indazoles were afforded from which two hits, compounds 1 (IC50 of 1.62 μΜ against Trypanosoma cruzi) and 2 (IC50 of 12.7 μΜ against Leishmania infantum) were revealed. Their IC50 are comparable to that of benznidazole (1.92 μM) and miltefosine (12.13 μM), which are FDA approved drugs for the treatment of T. cruzi and L. infantum respectively.

Share your ideas or questions with the authors!

Did you know that the greatest stimulus in scientific and cultural development is curiosity? Leave your questions or suggestions to the author!

Sign in to interact

Have a question or suggestion? Share your feedback with the authors!

Institutions
  • 1 University of São Paulo
  • 2 Universidade de São Paulo
  • 3 Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp
Track
  • BMOS-2026
Keywords
Combinatorial synthesis
Indazole derivatives
Phenotypic screening